CD274 and non-small cell lung carcinoma: In addition to PD-L1 expression, recent research indicated that TMB of 10 or more mut/Mb was associated with improved response and prolonged PFS in both tumor PD-L1 expression 1% or greater and less than 1% subgroups and was thus identified as a potential biomarker for first-line therapy of nivolumab plus ipilimumab in advanced NSCLC (29).